Begrænsede offentliggjorte data antyder dog, at sikkerhedsprofilen hos unge i 12- 16 års alderen, som behandles med 8 millioner IE Betaferon subkutant hver anden dag, svarer til sikkerhedsprofilen hos voksne.
However, limited published data suggest that the safety profile in adolescents from 12 to 16 years of age receiving Betaferon 8.0 million IU subcutaneously every other day is similar to that seen in adults.